PDT Partners’s Actinium Pharmaceuticals ATNM Stock Holding History

PDT Partners’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-11,539	Closed	-$112K	–	692
2020 Q3	$112K	Buy	+11,539	New	+$127K	0.01%	672

Other funds holding ATNM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PDT Partners's ATNM Position: Q4 2020 in Review

PDT Partners sold out of Actinium Pharmaceuticals (ATNM) in Q4 2020, closing a stake of 11,539 shares — an estimated $112K sold.

PDT Partners first reported a position in ATNM in Q3 2020 and held it in 1 quarter. The position peaked at $112K in Q3 2020. 48 funds tracked by Wall St. Rank hold ATNM as of Q4 2020.

PDT Partners reported no remaining Actinium Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
PDT Partners sold 11,539 Actinium Pharmaceuticals shares in Q4 2020, an estimated $112K.
PDT Partners first reported a position in Actinium Pharmaceuticals in Q3 2020 and held it in 1 quarter.
PDT Partners's Actinium Pharmaceuticals position peaked at $112K in Q3 2020.
48 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2020.

Based on PDT Partners's 13F filing for Q4 2020, filed 16 Feb 2021.